Goldstein David M sold $4K of ALMS

Wells Fargo downgraded its price target for Alumis to $18 from $25, a 28% decrease, while maintaining an Overweight rating. The new target implies a 193.6% upside from the Nov 12 close of $6.13, according to the bank.

Alumis reported 3Q 2026 revenue of $1.91M, down 8% YoY, with a net loss of $94.88M, improved 14% YoY. R&D expenses fell 17% due to completed trials. The company plans an NDA submission for envu in psoriasis by year-end and is exploring strategic alternatives for lonigutamab.

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.

Alumis presented Phase III trial results showing its psoriasis drug, envudeucitinib, achieved significant efficacy and safety milestones. The company plans to submit an NDA in Q4 2026, aiming to compete with Bristol Myers Squibb's Sotyktu, which had $291m in 2023 sales.